INDVNasdaqPharmaceutical PreparationsFiscal year ends December 31
Indivior Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$33.87+1.42 (+4.38%)
Close on Oct 19, 2026
- Market cap
- $4.20B
- P/E (TTM)
- 12.2
- Dividend yield
- –
Indivior Pharmaceuticals, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|
| SUBLOCADE | – | – | $630.00M | $408.00M | $244.00M | – | – |
| Marketed Products, PERSERIS | – | – | $42.00M | $28.00M | $17.00M | – | – |
| Sublingual/Other | – | – | $421.00M | $465.00M | $530.00M | – | – |
| PERSERIS | – | – | $42.00M | $28.00M | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|
| United States | – | – | $912.00M | $731.00M | $603.00M | – | – |
| Rest of World | – | – | $176.00M | $164.00M | $181.00M | – | – |
| United Kingdom | – | – | $5.00M | $6.00M | $7.00M | – | – |
From the segment and revenue-disaggregation notes of Indivior Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.